WaveMan
WaveMan · Company
LIVN · Livanova Plc
> Search tickers & screens ⌘K
LIVE
← All companies

LIVN LivaNova (LIVN) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001639691
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
176
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $668.6K priced

What the filings say about LIVN

Insiders, 180 days
-$1.0M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.7M
5 notices

LivaNova insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, LivaNova PLC insiders sold a net $1.0M of stock across 29 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Bianchi Francesco
Director
SELL
2026-09-14 SECtraded 2026-09-10
3,500
$273.0K
+1.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 31, 2026.
  • The trade is 78.9% of the 4,434 shares held after it.
  • 2 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bianchi Francesco sold about $273.0K of LIVN on Sep 10, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Story Brooke
Director
SELL
2026-09-08 SECtraded 2026-09-04
2,300
$187.3K
+2.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 18, 2025.
  • The trade is 30.7% of the 7,488 shares held after it.
  • 2 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Story Brooke sold about $187.3K of LIVN on Sep 4, 2026; 2 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Bianchi Francesco
Director
SELL
2026-09-02 SECtraded 2026-08-31
1,650
$131.5K
-0.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 15, 2026.
  • The trade is 20.8% of the 7,934 shares held after it.
  • 2 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bianchi Francesco sold about $131.5K of LIVN on Aug 31, 2026; 2 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Tezel Ahmet
Chief Innovation Officer
SELL
2026-08-13 SECtraded 2026-08-11
2,675
$207.9K
-1.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 43.9% of the 6,090 shares held after it.
  • 2 other insiders sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Innovation Officer Tezel Ahmet sold about $207.9K of LIVN on Aug 11, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 176 funds added in the latest 13F quarter.
Bianchi Francesco
Director
SELL
2026-06-17 SECtraded 2026-06-15
1,200
$96.2K
+2.7%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 26, 2026.
  • The trade is 12.5% of the 9,584 shares held after it.
  • No other insider sold within 30 days.
  • 176 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bianchi Francesco sold about $96.2K of LIVN on Jun 15, 2026; 176 funds added in the latest 13F quarter.
29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 24 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.0M over 180 days
-$799.8K over 90 days
below 62% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
176 funds bought in last quarter
more than 81% of Medical Devices
Revenue
+10.7% year over year
more than 52% of Medical Devices
Margin
-17.5% net margin
below 52% of Medical Devices
Buybacks
no share repurchases reported
Short interest
11.3% of the float short (float per yahoo 2026-10-27) · 10.6 days to cover · settled 2026-10-15
more than 91% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LIVN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+48.1%12M
-9%+13%+35%+57%2025-102025-122026-022026-042026-062026-082026-10 2026-09-10 · Bianchi Francesco sold $273.0K2026-08-11 · Tezel Ahmet sold $207.9K2026-09-04 · Story Brooke sold $187.3K2026-05-26 · Bianchi Francesco sold $136.3K2026-08-31 · Bianchi Francesco sold $131.5K2026-06-15 · Bianchi Francesco sold $96.2K2025-11-18 · Story Brooke sold $13.5K2026-09-10 · Bianchi Francesco filed to sell $273.0K2026-09-04 · Story Brooke filed to sell $187.3K2026-09-02 · Poletti Franco filed to sell $882.9K2026-08-31 · Bianchi Francesco filed to sell $131.5K2026-08-11 · Tezel Ahmet filed to sell $209.9K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LIVN: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
7,565,342 sh
$622.1M
PRIMECAP MANAGEMENT CO/CA/
4,168,377 sh
$342.8M
FMR LLC
3,147,068 sh
$258.8M
Hood River Capital Management LLC
2,565,477 sh
$211.0M
AQR CAPITAL MANAGEMENT LLC
2,356,191 sh
$191.0M

Congress trades in LIVN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LIVN planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Bianchi Francesco
Filed 2026-09-10
$273.0K
Story Brooke
Filed 2026-09-04
$187.3K
Poletti Franco
Filed 2026-09-02
$882.9K
Bianchi Francesco
Filed 2026-08-31
$131.5K
Tezel Ahmet
Filed 2026-08-11
$209.9K

LIVN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
DANA EPIPHANY SMALL CAP EQUITY FUND
$830.9K position · as of 2026-07-31
2.3%
Oberweis Micro-Cap Fund
$36.8M position · as of 2026-06-30
2.3%
Miller Market Neutral Income Fund
$8.0M position · as of 2026-07-31
2.2%
Miller Convertible Total Return ETF
$300.3K position · as of 2026-07-31
2.1%
Touchstone Variable Series Trust-Touchstone Small Company Fund
$1.2M position · as of 2026-06-30
1.9%
ROBO Global Healthcare Technology and Innovation ETF
$1.3M position · as of 2026-07-31
1.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr Mc Donald
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$8.6M
$2.6M
$2.1M
-26%
+14%
2021
$10.1M
$15.3M
$2.2M
+16%
+40%
2020
$6.9M
$5.7M
$1.7M
-12%
+18%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.0M sold by insiders over 180 days, 176 funds added last quarter, $1.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

LIVN financials

Revenue growth
+10.7%
XBRL, annual
Net margin
-17.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.5B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+12.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$148.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.22x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.85x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+15.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+7.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate -76%, not meaningful
Return on capital employed
+10.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
23.85x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$4.2B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+3.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.4B$1.3B$1.2B$1.0B
Gross profit$939.9M$853.5M$755.8M$707.2M
Operating income$199.4M$129.1M-$68.5M-$76.8M
Net income-$242.5M$63.2M$17.6M-$86.2M
EPS (diluted)-4.451.160.32-1.61
Operating cash flow$254.3M$183.0M$74.9M$69.9M
Cash$635.6M$428.9M$266.5M$214.2M
Long-term debt$345.2M$549.6M$568.5M$518.1M
SEC XBRL, fiscal years, as known on 2026-10-28

LIVN Stock Sonar score 6/7 axes

Find similar shapesCompare

LIVN ranks highest on profitability (83rd percentile) and institutional and government (81st), and lowest on insider conviction (18th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
83
Inputs
  • Return on equity+15.4% · 84 pct, sector of 183
  • Return on assets+7.3% · 82 pct, sector of 214
  • Return on invested capitaleffective tax rate -76%, not meaningful
  • Return on capital employed+10.4% · 83 pct, sector of 188
Financial health
73
Inputs
  • Debt to equity0.22x · 56 pct, sector of 159
  • Cash flow to debt0.85x · 89 pct, sector of 150
Growth
52
Inputs
  • Revenue growth, YoY+10.7% · 52 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
18
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.0M · 35 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
81
Inputs
  • Funds adding, latest quarter176 · 81 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
44
Inputs
  • Short interest, % of float+11.3% · 16 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+20.9% · 16 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LIVN filings, in plain words

Are LivaNova insiders buying or selling LIVN?

In the 180 days to 2026-10-28, LivaNova insiders were net sellers, a net $1.0M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of LIVN?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.7M of stock; the latest, by Bianchi Francesco, was filed 2026-09-10.

Read the full summary

In the 180 days to 2026-10-28, LivaNova insiders were net sellers of LIVN, a net $1.0M across purchases and sales reported on Form 4 by 3 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies